ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO887

Translating the Findings of DAPA-CKD to Reductions in Healthcare Resource Utilization and Costs

Session Information

Category: CKD (Non-Dialysis)

  • 2202 CKD (Non-Dialysis): Clinical‚ Outcomes‚ and Trials


  • McEwan, Philip, Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom
  • Miller, Ryan, Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom
  • Garcia Sanchez, Juan Jose, AstraZeneca PLC, Cambridge, Cambridgeshire, United Kingdom
  • Barone, Salvatore, AstraZeneca R&D, Gaithersburg, Maryland, United States
  • Nolan, Stephen, AstraZeneca PLC, Cambridge, Cambridgeshire, United Kingdom
  • Jha, Vivekanand, The George Institute for Global Health, Newtown, New South Wales, Australia
  • Correa-Rotter, Ricardo, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico
  • Chernin, Gil, Kaplan Medical Center, Rehovot, Israel
  • De Nicola, Luca, Universita degli Studi della Campania Luigi Vanvitelli Scuola di Medicina e Chirurgia, Napoli, Italy

Dapagliflozin reduced the risk of kidney failure and all cause, including cardiovascular, mortality in CKD patients with and without type 2 diabetes in the Study to Evaluate the Effect of Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD). The trial was stopped early due to overwhelming efficacy, with a 39% reduction in the incidence of the primary composite endpoint (≥50% eGFR decline, end-stage kidney disease (ESKD) and renal/cardiovascular death). This project aimed to estimate the impact on healthcare resource use and costs.


Event rates in dapagliflozin and placebo arms of the DAPA-CKD trial were used to predict the incidence of components of trial endpoints over a three-year period. Cost-offsets versus standard of care without dapagliflozin (SOC) were estimated by applying published US costs to the incidence of events. Those attributed to a ≥50% decline in eGFR were based on the resulting CKD stage compared with baseline CKD stage. Dapagliflozin costs were excluded. Results were estimated in a treated population of 10,000 people. Analysis of 10,000 people aged <65 years and 10,000 people ≥65 years was also conducted. Results for the USA will be supplemented with further analysis for a total of 32 countries.


Over a three-year period, the estimation predicted 750 cases of ≥50% decline in eGFR with dapagliflozin versus 1,340 with SOC (590 fewer events, number needed to treat [NNT]: 17). 355 ESKD events would be avoided with dapagliflozin (722 vs 1,077, NNT: 28) as would 231 hospitalisations for heart failure (HHF) compared with SOC (237 vs 468, NNT: 43) and 249 deaths (638 vs 887, NNT: 40). Reduced incidences of adverse clinical outcomes were estimated to give cumulative medical care cost-offsets of $126.9M per 10,000 treated patients, $223.0M per 10,000 treated patients aged <65 years and $61.9M per 10,000 treated patients aged ≥65 years, or 34%, 38%, and 25% reductions compared with SOC, respectively.


Dapagliflozin treatment in CKD has the potential to significantly reduce healthcare resource use through delayed CKD progression and reduced incidence of cardio-renal events and mortality.


  • Commercial Support –